Document resource
The controversial1 Alzheimer’s drug lecanemab has overcome another regulatory hurdle, with Australia’s drugs regulator approving the therapy after two rejections.2
Annotated abstract
Lecanemab: Controversial Alzheimer’s drug approved by Australian drugs regulator after two rejections
bmj · 2025-09-30 · canonical JSON source